IL316308A - Modifying binding molecules to minimize pre-existing interactions - Google Patents
Modifying binding molecules to minimize pre-existing interactionsInfo
- Publication number
- IL316308A IL316308A IL316308A IL31630824A IL316308A IL 316308 A IL316308 A IL 316308A IL 316308 A IL316308 A IL 316308A IL 31630824 A IL31630824 A IL 31630824A IL 316308 A IL316308 A IL 316308A
- Authority
- IL
- Israel
- Prior art keywords
- level
- seq
- monoclonal antibody
- subject
- component
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695988P | 2018-07-10 | 2018-07-10 | |
| PCT/US2019/041203 WO2020014358A1 (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316308A true IL316308A (en) | 2024-12-01 |
Family
ID=67544330
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316308A IL316308A (en) | 2018-07-10 | 2019-07-10 | Modifying binding molecules to minimize pre-existing interactions |
| IL279803A IL279803A (en) | 2018-07-10 | 2020-12-27 | Modifying binding compounds to minimize given interactions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279803A IL279803A (en) | 2018-07-10 | 2020-12-27 | Modifying binding compounds to minimize given interactions |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11448651B2 (https=) |
| EP (1) | EP3820891A1 (https=) |
| JP (2) | JP7665339B2 (https=) |
| KR (1) | KR102938177B1 (https=) |
| CN (1) | CN112543768B (https=) |
| AR (1) | AR115730A1 (https=) |
| AU (1) | AU2019302642B2 (https=) |
| BR (1) | BR112020026784A2 (https=) |
| CA (1) | CA3104873A1 (https=) |
| EA (1) | EA202190228A1 (https=) |
| IL (2) | IL316308A (https=) |
| MX (2) | MX2021000239A (https=) |
| MY (1) | MY202673A (https=) |
| SG (1) | SG11202012835RA (https=) |
| TW (2) | TW202428612A (https=) |
| WO (1) | WO2020014358A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019302642B2 (en) | 2018-07-10 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
| US20260008857A1 (en) * | 2024-06-13 | 2026-01-08 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2644663A1 (en) | 2006-03-23 | 2007-09-27 | Kirin Pharma Kabushiki Kaisha | Agonist antibody to human thrombopoietin receptor |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| AU2008348252A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| CN105218673A (zh) * | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| CA2741114A1 (en) | 2008-10-24 | 2010-04-29 | Cornelis Lammert Verweij | Biomarkers for predicting the development of chronic autoimmune diseases |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| WO2010122148A1 (en) | 2009-04-24 | 2010-10-28 | Boehringer Ingelheim International Gmbh | An improved antibody domain and antibody fragments and antibodies based thereon |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| WO2011074965A1 (en) | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| WO2012166588A2 (en) | 2011-06-01 | 2012-12-06 | Morehouse School Of Medicine | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| SG2014010482A (en) * | 2011-08-17 | 2014-04-28 | Glaxo Group Ltd | Modified proteins and peptides |
| TW201444872A (zh) | 2013-03-06 | 2014-12-01 | Merrimack Pharmaceuticals Inc | 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體 |
| TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| CN117442748A (zh) | 2014-10-02 | 2024-01-26 | 希望之城公司 | 多价中间表位、中间表位结合抗体及其用途 |
| BR112017004810A2 (pt) | 2014-11-05 | 2017-12-12 | Hoffmann La Roche | imunoensaio |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| AU2016344665C1 (en) * | 2015-10-29 | 2023-07-27 | F. Hoffmann-La Roche Ag | Anti-variant Fc-region antibodies and methods of use |
| US20170137535A1 (en) | 2015-10-30 | 2017-05-18 | Genentech, Inc. | Anti-factor d antibody formulations |
| BR112019004733A2 (pt) | 2016-09-19 | 2019-05-28 | Celgene Corp | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| WO2019101863A1 (en) | 2017-11-22 | 2019-05-31 | Vacara Ab | Antibodies to citrullinated proteins |
| AU2019302642B2 (en) | 2018-07-10 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
| WO2020246891A1 (en) | 2019-06-07 | 2020-12-10 | Sanquin Innovatie B.V. | Methods and compounds for typing rheumatoid factors |
-
2019
- 2019-07-10 AU AU2019302642A patent/AU2019302642B2/en active Active
- 2019-07-10 CA CA3104873A patent/CA3104873A1/en active Pending
- 2019-07-10 AR ARP190101943A patent/AR115730A1/es unknown
- 2019-07-10 US US16/507,880 patent/US11448651B2/en active Active
- 2019-07-10 JP JP2020572773A patent/JP7665339B2/ja active Active
- 2019-07-10 KR KR1020217002619A patent/KR102938177B1/ko active Active
- 2019-07-10 WO PCT/US2019/041203 patent/WO2020014358A1/en not_active Ceased
- 2019-07-10 MX MX2021000239A patent/MX2021000239A/es unknown
- 2019-07-10 IL IL316308A patent/IL316308A/en unknown
- 2019-07-10 EA EA202190228A patent/EA202190228A1/ru unknown
- 2019-07-10 TW TW113110335A patent/TW202428612A/zh unknown
- 2019-07-10 TW TW108124293A patent/TWI838388B/zh active
- 2019-07-10 EP EP19749878.5A patent/EP3820891A1/en active Pending
- 2019-07-10 SG SG11202012835RA patent/SG11202012835RA/en unknown
- 2019-07-10 CN CN201980042886.7A patent/CN112543768B/zh active Active
- 2019-07-10 MY MYPI2020006898A patent/MY202673A/en unknown
- 2019-07-10 BR BR112020026784-8A patent/BR112020026784A2/pt unknown
-
2020
- 2020-12-27 IL IL279803A patent/IL279803A/en unknown
-
2021
- 2021-01-07 MX MX2025013509A patent/MX2025013509A/es unknown
-
2022
- 2022-09-19 US US17/933,185 patent/US12523659B2/en active Active
-
2025
- 2025-04-09 JP JP2025064335A patent/JP2025100662A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019302642A1 (en) | 2021-02-25 |
| EP3820891A1 (en) | 2021-05-19 |
| CN112543768A (zh) | 2021-03-23 |
| KR102938177B1 (ko) | 2026-03-11 |
| EA202190228A1 (ru) | 2021-04-14 |
| MX2021000239A (es) | 2021-03-25 |
| US12523659B2 (en) | 2026-01-13 |
| SG11202012835RA (en) | 2021-01-28 |
| CN112543768B (zh) | 2024-05-03 |
| AU2019302642B2 (en) | 2025-10-30 |
| US20200018754A1 (en) | 2020-01-16 |
| WO2020014358A1 (en) | 2020-01-16 |
| JP7665339B2 (ja) | 2025-04-21 |
| MY202673A (en) | 2024-05-14 |
| AR115730A1 (es) | 2021-02-17 |
| TW202428612A (zh) | 2024-07-16 |
| IL279803A (en) | 2021-03-01 |
| US11448651B2 (en) | 2022-09-20 |
| TWI838388B (zh) | 2024-04-11 |
| MX2025013509A (es) | 2025-12-01 |
| JP2021531245A (ja) | 2021-11-18 |
| CA3104873A1 (en) | 2020-01-16 |
| TW202021984A (zh) | 2020-06-16 |
| JP2025100662A (ja) | 2025-07-03 |
| US20230266333A1 (en) | 2023-08-24 |
| BR112020026784A2 (pt) | 2021-03-30 |
| KR20210030378A (ko) | 2021-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523401A5 (https=) | ||
| KR20240006702A (ko) | 진단용 최종 당화 산물 항체 | |
| CN109311983B (zh) | 人源化抗clever-1抗体及其用途 | |
| RU2013141134A (ru) | Антитела, которые специфично связывают альфа-токсин staphylococcus aureus, и способы их применения | |
| JP2015530868A5 (https=) | ||
| JP2014521089A5 (https=) | ||
| JP2017507131A5 (https=) | ||
| JP5305903B2 (ja) | 感染症の検出方法 | |
| JP6564435B2 (ja) | アルファ４ベータ７ヘテロ二量体特異抗体の投与 | |
| Costa et al. | Diagnosis of human strongyloidiasis: Application in clinical practice | |
| RU2017114396A (ru) | Способ измерения реактивности fviii | |
| IL316308A (en) | Modifying binding molecules to minimize pre-existing interactions | |
| US12055552B2 (en) | Method for diagnosis based on circulating extracellular vesicles | |
| JP2017523130A5 (https=) | ||
| JP2009515183A5 (https=) | ||
| Sung et al. | Prediction of functional outcome in axonal Guillain-Barre syndrome | |
| JP2021531245A5 (https=) | ||
| Lucendo et al. | Emerging therapeutic strategies for eosinophilic esophagitis | |
| WO2017149122A1 (en) | Clinical assessment of m-protein response in multiple myeloma | |
| JP2014515743A (ja) | Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 | |
| JPWO2020014358A5 (https=) | ||
| WO2021033196A1 (en) | Methods, compositions and kits for snake venom detection | |
| JP2021522478A (ja) | 選択された患者の心血管疾患を治療するための組成物および方法 | |
| WO2014104305A1 (ja) | プレセプシン測定による炎症性腸疾患の診断 | |
| JP7386540B2 (ja) | アルドステロン産生腺腫と特発性アルドステロン症の識別の為の試験方法及び診断用負荷試験剤 |